Thromboembolic and haemorrhagic events in permanent atrial fibrillation: Observational study in an emergency department

European Journal of Internal Medicine

Volumn 20, Issue 8, 2009, Pages 756-759

  Rovellini, Angelo ^a   Folli, Christian ^a   Cardani, Francesca ^a   Monzani, Valter ^a  

^a IRCCS   (Italy)

Author keywords

Anti thrombotic therapy; Atrial fibrillation; Haemorrhage; Oral anticoagulation; Stroke; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

AGED; ARTICLE; BLEEDING DISORDER; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; THROMBOEMBOLISM; ATRIAL FIBRILLATION; CHI SQUARE DISTRIBUTION; COMPLICATION; EMERGENCY HEALTH SERVICE; HEMORRHAGE; NONPARAMETRIC TEST; PROSPECTIVE STUDY; RISK FACTOR; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; EMERGENCY SERVICE, HOSPITAL; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; STROKE; THROMBOEMBOLISM;

EID: 70449122148     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2009.08.008     Document Type: Article

References (22)

1. Fuster V., Rydén L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8 9 (2006) 651-745
2. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 18 (2001) 2370-2375
3. Nieuwlaat R., Capucci A., Camm A.J., Olsson S.B., Andresen D., Davies D.W., et al. Atrial Fibrillation management: a prospective survey in ESC membre countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26 (2005) 2422-2434
4. Sherman D.G., Kim S.G., Boop B.S., Corley S.D., Dimarco J.P., Hart R.J., et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 165 (2005) 1185-1191
5. Nieuwlaat R., Olsson S.B., Lip G.Y., Camm A.J., Breithardt G., Capucci A., et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 153 (2007) 1006-1012
6. Nieuwlaat R., Capucci A., Lip G.Y., Olsson S.B., Prins M.H., Nieman F.H., et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 27 (2006) 3018-3026
7. Go A.S., Hylek E.M., Chang Y., Phillips K.A., Henault L.E., Capra A.M., et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA 290 (2003) 2685-2692
8. Fang M.C., Chang Y., Hylek E.M., Rosand J., Greenberg S.M., Go A.S., et al. Advanced age, anticoagulation intensity, and risk for intracranial haemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141 (2004) 745-752
9. Gallagher A.M., Rietbrock S., Plumb J., and Van Staa T.P. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J ThrombHaemost 6 (2008) 1500-1506
10. Meiltz A., Zimmerman M., Urban P., and Bloch A. Atrial fibrillation management by practice cardiologist: a prospective survey on the adherence to guidelines in the real world. Europace 10 (2008) 671-680
11. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., and Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001) 2864-2870
12. Friberg L., Hammar N., Ringh M., Pettersson H., and Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 27 (2006) 1954-1964
13. Sudlow M., Thomson R., Thwaites B., Rodgers H., and Kenny R.A. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. The Lancet 352 (1998) 1167-1171
14. Hirsh J., Guyatt G., Albers G.W., Harrington R., and Schünemann H.J. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 6 (2008) 110S-112S
15. Go A.S., Hylek E.M., Borowsky L.H., Phillips K.A., Selby J.V., and Singer D.E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131 (1999) 927-934
16. Monte S., Macchia A., Pellegrini F., Romero M., Lepore V., D'Ettorre A., et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 27 (2006) 2217-2223
17. Gage B.F., Yan Y., Milligan P.E., Waterman A.D., Culverhouse R., Rich M.W., et al. Clinical classification schemes for predicting haemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151 (2006) 713-719
18. Devereaux P.J., Anderson D.R., Gardner M.J., Putnam W., Flowerdew G.J., Brownell B.F., et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 323 (2001) 1-7
19. Hughes M., and Lip G.Y. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 99 (2008) 295-304
20. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994) 1449-1457
21. Hylek E.M., and Magnani J.W. Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation. Europace 10 (2008) 3-5
22. Jones M., McEwan P., Morgan C.L., Peters J.R., Goodfellow J., and Currie C.J. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 91 (2005) 472-477